
News|Articles|November 30, 2012
FDA approves cabozantinib to treat rare type of thyroid cancer
FDA has approved cabozantinib (Cometriq, Exelixis and AstraZeneca) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ACIP to vote on major hepatitis B vaccine update that could reshape the childhood vaccine schedule
2
Transplant-fueled hybrid immune systems may help reverse Type 1 diabetes
3
New test may solve the specificity and false-positive problems of the PSA test for prostate cancer
4
Clinical self-hypnosis improves hot flash symptoms, study shows
5






















































